• pharma
  • pharmapharma

CONFERENCE

rss_Pharma.jpg...see all
Vaccine Research & Innovation 2011

Vaccine Research & Innovation 2011

Exploring global opportunities in vaccine research and development

10th - 11th February 2011, BSG Conference Centre, London, UK

  1. Background Info
  2. Day 1
  3. Day 2
  4. Partners
  5. Past Papers
  6. Venue Info
  7. Speakers
Silver Sponsors
  • Encorium
  • BIA Separations
  • EUFETS GmbH
Media Partners
  • PharmiWeb.com
  • BIOTECHNOLOGY EUROPE
  • Future Pharmaceuticals
  • InPharm
  • Pharma Connections Worldwide

Background Info

Key Speakers
• Guido Grandi, Senior Project Leader, Novartis Vaccines and Diagnostics
• Dr Alex Kudrin, Medical Assessor, Biological PLAT, MHRA
• Dr Bassam Hallis, General Project Manager, Centre for Emergency Preparedness and Response, Health Protection Agency
• Dr Jon Heinrichs, Senior Research Fellow, Vaccine Basic Research, Merck
• Dr Carmen Giefing, Group Leader, Antigen Identification - Molecular Microbiology, Intercell
• Dr David Kirke, Associate Director of Regulatory Affairs, ERA Consulting
• Dr Barbara Guinn, Cancer Sciences Division, University of Southampton
• Jean Marc Balloul, New Venture Development Director, Transgene
• Lior Carmon, Founder & CEO, Vaxil Biotherapeutics 
• Dr. Matjaz Peterka, Head, MB laboratory

Increasing use of novel technologies has boosted the vaccines industry worldwide. Recent technological breakthroughs in vaccine research, manufacturing and delivery, promise a bright future for the new generation of vaccines, particularly for chronic conditions such as cancer, auto-immune diseases and nicotine addiction.

According to Visiongain's recent report, The Global Vaccines Market, 2008-2023, therapeutic vaccines will significantly expand the vaccines market contributing to rapid revenue growth during the period 2008 to 2023. The cancer vaccine market, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvant, and vaccine manufacturing.

Our Vaccine Research & Innovation conference is designed to implement successful strategies and innovative technologies to develop more effective vaccines. Gain insights through industry led case studies and discussions with key decision markers from the vaccines sector. Network and collaborate with global professionals to keep up-to-date with future trends and exploring business opportunities at the two-day event. 

By attending this conference you will gain insights on
• Overcoming challenges to cancer vaccine development 
• Evaluating the immune response to combination vaccines
• Accelerating new vaccine introduction in the developing world
• Monitoring High sensitivity T cell immune mechanism of novel vaccines, gene therapy, protein based drugs
• Assessing the key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines
• Examining the safety challenges on new vaccine introduction
• Implementing strategies for manufacturing and purification of conjugate vaccines
• Good supply chain management practices for vaccine distribution

Who will be there?
Presidents, Chief Executives, VPs, Global Heads, Scientific Advisors, Therapeutic Area Heads, in:
• Vaccine equipment and manufacturing
• Vaccine application development
• Vaccinology and molecular biology
• Cell line engineering
• Proteomics, recombinant protein/DNA biotechnology
• Infectious disease R&D
• In-licensing and out-licensing
• Pharmacovigilance and safety testing
• Regulatory affairs
• Strategic product development
• External research
• Manufacturing/production
• Chemistry manufacturing and controls (CMC)
• Procurement & purchasing
• Cold chain supply and lyophilisation
• Strategic alliances
• Clinical product resourcing
• Supply outsourcing project management
• Contract management
• Process development
• Business development
• Drug discovery & delivery
• Patent law
• Investment and venture capital

Day 1

Day One, Thursday 10 February 2011

09:30 Registration and refreshments

10:00 Opening address from the chair

Dr David Kirke
Associate Director of Regulatory Affairs
ERA Consulting 

10:10 Regulatory challenges in the approval process for novel vaccine adjuvants
• Regulation and evaluation process of new adjuvants in vaccines
• Differences in the global regulatory requirements and overcoming these challenges
• Engaging with the regulators and contributing to the evolution of the regulatory framework
• Integrating your global regulatory strategy and product development plan

Dr David Kirke
Associate Director - Regulatory Affairs
ERA Consulting

10:50 Evaluating the immune response to combination vaccines
• High sensitivity T cell immune monitoring of novel vaccines, gene therapy, protein based drugs
• Immune monitoring during pre clinical and clinical trials to detect adverse immune reactions to gene therapy and protein based drugs early

Dr Thomas O Kleen
Director, Business and Technology Development
Cellular Technology

11:30 Morning refreshments

11:50 Development of a cellular cancer vaccine
• Scientific background for choice of cancer vaccine
• Development of manufacturing processes
• Development of QC methods
• Preclinical characterization of cellular cancer vaccine

Dr Klaus Kühlcke
Eufets

12.10 Development of avian cell lines dedicated to vaccines manufacturing 
• Human vaccine (Flu, Flavivirus, Recombinant Poxvirus)
• Veterinary Vaccine
• Therapeutic proteins

Jean Marc Balloul
New Venture Development Director
Transgene

12:50 Networking lunch

13:50 Leveraging a CRO in accelerating vaccine development
• Agility in a regulated environment 
• Experiences
• Efficiencies

Representative
Encorium

14:10 Development of a 15-valent pneumococcal - conjugate vaccine
• Global epidemiological trends following pneumococcal-conjugate vaccine introduction  
• Development of a polysaccharide-conjugate vaccine with expanded serotype coverage
• Evaluation of vaccine immunogenicity in rabbit and infant-monkey model systems

Dr Jon Heinrichs
Senior Research Fellow, Vaccine Basic Research
Merck

14:50 Afternoon refreshments

15:10 Presentation TBC

Dr. Matjaz Peterka
Head
MB laboratory

15:30 Regulatory and clinical development challenges with cancer vaccines
• Current status of new therapeutic vaccines development;
• Clinical lessons and learning's from recent product development;
• Regulatory principles and guidelines on clinical development of new therapeutic vaccines

Dr Alex Kudrin
Medical Assessor, Biological PLAT
MHRA

16:10 Challenges to cancer vaccine development
• Overview of the main immune responses
• Identifying targets for immune therapy
• New vaccine development and current clinical trials

Dr Barbara Guinn
Cancer Sciences Division
University of Southampton

16:50 Closing remarks from the chair

17:00 Networking drinks 
 

Day 2

Day Two, Friday 11 February 2011

09:30 Registration and refreshments

10:00 Opening address from the chair 

Dr David Kirke
Associate Director of Regulatory Affairs
ERA Consulting

10:10 Development of a pneumococcal vaccine comprising highly conserved proteins
• Discovery of a novel class of highly conserved vaccine antigens
• Approach for new-generation vaccines is the use of nonpolysaccharide antigens that are conserved among pneumococcal strains
• Changing epidemiology of pneumococcal infection
• Immunological considerations and correlates

Dr Carmen Giefing
Group Leader, Antigen Identification - Molecular Microbiology
Intercell

10:50 From trial and error to rational design of adjuvant vaccines
• Adjuvant need not induce side effects: A different concept
• ISCOM, adjuvant for newborns and elderly
• Antigen sparing an essential aspect
• Broadening of immune response

Bror Morein
Department of Medical Sciences, Virology, Uppsala University and Chairman of the Scientific Advisory Board
Isconova

11:30 Morning refreshments

11:50 Case Study: Key immunological observations on clinical development of pandemic influenza A (H1N1) vaccines

Dr Bassam Hallis
General Project Manager, Centre for Emergency Preparedness and Response
Health Protection Agency

12:30 Vaccine Development & early clinical research (Phase I)
• Phase I Study Design
• Managing Sponsors
• Managing the Vaccine
• Operational Execution

Andrew Nolan
Senior Project Manager, Phase I Therapeutic Area Head – Vaccines
Quintiles

13:10 Networking lunch

14.10 Case study: Developing the next generation of therapeutic vaccines
The case study will feature novel, therapeutic vaccines for the treatment of cancer and key intracellular pathogens via specific manipulation and augmentation of the patient cellular immune responses.

Lior Carmon 
Founder & CEO
Vaxil Biotherapeutics

14:50 Surface proteome analysis as a fast-track to vaccine discovery
• Stripping away cell-surface proteins
• Mass-spectrometry and in silico surfome analysis
• Identification and validation of new targets for group A Streptococcus

Guido Grandi
Senior Project Leader
Novartis Vaccines and Diagnostics

15:30 Afternoon refreshments

15:50 Vaccine Development of HIV-1 vaccines inducing protective T cell responses
• Design and pre-clinical evaluation
• Towards an HIV T cell-based vaccine
• Strategies eliciting HIV-1-specific T cell responses
• Natural proteins as vaccine antigens

Dr Tomas Hanke
Reader in Immunology, Group Head/PI Supervisor, HIV-1 Vaccine Development
Weatherall Institute of Molecular Medicine

16:30 Chair’s closing remarks

16:40 End of Conference 

Partners

Silver Sponsors:

Encorium
Encorium is a full service CRO with experience in more than 30 countries worldwide. With expertise and investigator networks we have serviced successfully over 20 clients and recruited over 55,000 subjects/patients in pediatric, adult and elderly populations for prophylactic and therapeutic vaccine.
By establishing a global CRO network Encorium is strengthening its offerings in vaccine development.
Encorium ensures efficiency in clinical trial design and execution. Having been trusted the conduct of some of the largest vaccine studies performed we understand that our success is rooted in our clients success and we are committed to becoming a world leading vaccine CRO. For further information, please visit www.encorium.com

EUFETS GmbH
EUFETS GmbH, a subsidiary of BioNTech AG, is a GMP service company with >10 years experience in cell and gene therapy. EUFETS has produced retroviral vectors for clinical trials performed in various European countries and has manufactured gene-modified patient- and donor cells for clinical trials on stem cell gene therapy and T cell gene therapy. Furthermore, EUFETS has experience in the production and characterization of cellular and RNA-based tumour vaccines.
In addition, the company is specialized in the development of customized analytical methods for bioactive molecules that can be performed under GMP and GLP conditions. For more information please visit  www.eufets.com 

BIA Separations
BIA Separations develops and produces CIM® Monolithic Columns. These revolutionary chromatographic supports are designed for biomolecule (pDNA, virus, protein) purification, process development, and production. CIM® supports combine the separation power, capacity, and sample distribution advantages that customers expect from chromatographic supports and the additional benefit of convective mass transport which results in much faster separations (biomolecules maintain their activitiy), high volumetric throughput, and low back pressure. Since all columns (lab through industrial scale) are made of the same material, CIM® Monolithic Columns maintain excellent performance characteristics across all scales making them ideal for the development of a robust virus and other biomolecule purification processes that can be quickly and efficiently scaled up with potential cost savings. For further information, please visit www.biaseparations.com

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

Future Pharmaceuticals
Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide. For further information, please visit www.futurepharmaus.com

InPharm
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com

Pharma Connections Worldwide
Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. For further information please visit www.pharmaconnections.com

Enquiries

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's Vaccine Research & Innovation 2011 conference, please contact:
Ronald Magali, Sponsorship and Account Manager, +44 (0)20 7549 9934
Ronald.magali@visiongainglobal.com 

Past Papers

Speaker presentations are free to delegates. If you are unable to attend the event, the presentations are published two weeks after the event and are available to purchase.

Venue Info

The visiongain event is to be held at BSG House, London. The address of the venue is:
BSG House, 226-236 City Road, London EC1V 2QY
Click for Google maps.

Directions to the venue:
The nearest airports are:

London/Heathrow - LHR
• By train: take the Heathrow Express to Paddington. Change onto the London Underground - Hammersmith & City Line (pink) to King’s Cross, change to the Northern Line (black) to Old Street
• By taxi: Approx. distance: 20 miles / 33KM. Approx. cost: GB£50.00. Approx. time: 1hour 20 mins

London/Gatwick - LGW
• By train: take the Gatwick express to Victoria. Change onto the London Underground - Victoria Line (light blue) to King’s Cross, change to the Northern Line (black) to Old Street.
• By taxi: Approx. distance: 35 miles / 56KM. Approx. cost: GB£60.00. Approx. time: 1hour 20 mins

London City – LCY
• By train: take the Docklands Light Railway to Bank station. Change onto the London Underground - Northern Line (black) to Old Street.
• By taxi: Approx. distance: 6 miles / 9KM. Approx. cost: GB£25.00. Approx. time: 45 mins
Please note these timings and prices are given only as an indication. During peak hours they are subject to increase.
If you wish to pre-arrange travel by taxi and prices with a local taxi company, Addison Lee can be contacted on +44 (0) 20 7387 8888

Eurostar St Pancras International
By train: Change onto the London Underground at King’s Cross – Northern Line (black) to Old Street.
By taxi: Approx. distance: 1.8 miles / 2.89 KM Approx. cost: GB £7.00 Approx. time: 5 minutes
Please note these timings and prices are given only as an indication. During peak hours they are subject to increase.

The nearest major train stations are:
• King’s Cross – take the London Underground - Northern line (black) to Old Street
• Liverpool Street – take the London Underground – Hammersmith & City (pink), Circle (yellow) or Metropolitan lines (maroon) to Moorgate. Change onto the Northern line (black) to Old Street
• Waterloo – take the London Underground – Jubilee line (grey) to London Bridge. Change onto the Northern Line (black) to Old Street

Walking from Old Street station:
Take exit 8 from the station and follow the green line on the floor to Moorfields Eye Hospital, continue on past there for 3-4 minutes, you will see a blue sign on the side of the building saying BSG. This is BSG House, 226-236 City Road.

Venue facilities include:
BSG House features wi-fi internet access and the possibility of using additional meeting rooms. Please contact visiongain for further information.

Local Accommodation:

Here are a list of recommended local hotels
Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Approximately a 10 minute walk to BSG House and close to Old Street tube station and Moorgate which is just 0.5 miles away. The hotel has a breakfast restaurant area and is close to a range of bars and restaurants with attractions including the Globe Theatre and St Pauls Cathedral close by.
Jury’s Inn Islington, 60 Pentonville Road, Islington, London N1 9LA. Tel: +44 (0) 207 282 5500
This hotel is a short journey, or 20-minute walk, away from the conference venue. It is a few minutes walk from Angel tube station and close to King’s Cross, and Euston stations. Also close by is Upper Street (Islington) which has many restaurants, cafes and bars. The rooms offer satellite TV, and internet connections. The hotel has both a bar and restaurant. Standard double room – Single occupancy £98, including breakfast £105, Double occupancy only £98 including breakfast £112. Call reservations on +44 (0) 207 282 5500 and quote Visiongain on booking. This offer is subject to availability.
Hilton London Islington, 53 Upper Street, Islington, London, N1 0UY Tel: +44 (0) 207 354 7700
Probably the furthest from the venue of all of our recommended hotels, but probably the most up-market of the local hotels. Close to Upper Street (Islington) which has plenty of dining and drinking options. Also nearby to Angel tube station and a short cab ride from King’s Cross. The hotel offers wi-fi and a business centre, and a restaurant and bar. Each guest room offers internet access, satellite TV channels and a desk.
London City Holiday Inn Express, 275 Old Street, London, EC1V 9LN Tel: +44 (0) 207 300 4300
Approximately a 10 minute walk to BSG House and close to Old Street tube station, this hotel offers a restaurant and a range of business services, including high-speed internet access in all rooms and the lobby area. The hotel is ideally located for the fashionable bars and restaurants of areas of Hoxton, Shoreditch and Clerkenwell.

The best to see in your host city:

Places to eat:
• Fifteen, 15 Westland Place, N1 7LP T: +44 (0)871 330 1515 – Italian/Fusion
• Carluccio’s Caffe, 305-307 Upper Street, N1 2TU, T: +44 (0) 207 359 8167 – Italian
• Hanoi Café, 98 Kingsland Road, E2 8DP, T: 020 7729 5610 – Vietnamese
• Isarn, 119 Upper Street, N1 1QP, T: 0207 424 5153 – Thai
• Moro, 34-36 Exmouth Market, EC1R 4QE, T: 020 7833 8336 - Spanish

Places to drink:
All of the bars listed do serve food during peak hours
• The Eagle, 2 Shepherdess Walk, City Road, London N1 7LB, T: +44 (0) 20 7553 7681
• Cantaloupe Bar, 35-42 Charlotte Street, London, EC2A 3PB T: +44 (0) 20 7613 4411
• Bavarian Beerhouse, 190 City Road London EC1V 2QH, T: +44 (0) 20 760 80 925
Also Upper Street in Angel Islington, just a short taxi ride away, has a large number of bars and restaurants offering a wide range of cuisine.

If you have the time:
St Pauls Cathedral (1 MI / 1.61 KM )
British Museum (1 MI / 1.61 KM )
Oxford Street * Great for shopping * (1.5 MI / 2.41 KM )
Tower of London (2 MI / 3.22 KM )
Tate Modern (2 MI / 3.22 KM )
London Eye (2 MI / 3.22 KM )
Westminster Abbey (2.5 MI / 4.02 KM )
Houses of Parliament (2.5 MI / 4.02 KM )

Please note: The information contained herein is intended for guidance purposes only. The responsibility to ensure accuracy of the details before visiting remains that of the individual. Visiongain can not be held responsible for any losses resulting from actions taken on the above information.
 

Speakers

Speaker bios: 

  • Dr Tomáš Hanke

    Dr Tomáš Hanke

    Reader in Immunology, Group Head/PI Supervisor, HIV-1 Vaccine Development

    Weatherall Institute of Molecular Medicine

    Dr Tomáš Hanke pioneered for HIV-1 a vaccine platform based on the DNA-modified vaccinia virus Ankara (MVA) regimen. At present, he focuses on the development of vaccines based on the conserved regions of the HIV-1 proteome. In addition to a busy preclinical vaccine development programme, he currently co-ordinates two EDCTP-funded infant HIV-1 vaccine trials in Kenya and the Gambia, and oversees two MRC-funded adult clinical trials in Oxford, UK.

  • Dr. Klaus Kühlcke

    Dr. Klaus Kühlcke

    Managing Director

    EUFETS GmbH

    Klaus Kühlcke presently holds the position of Manging Director at EUFETS GmbH in Idar-Oberstein, Germany. EUFETS, a subsidary of the BioNTech AG in Mainz, Germany, is developing cancer vaccine products for the mother company and provides contract manufacturing services for cell- and gene therapy. Dr. Kühlcke has been with the company since its foundation in 1997. Previously he has held the position of “Director QC” “Qualified Person”, “Scientific Director”, “ Vice President Operations”.

  • Dr. Thomas O. Kleen

    Dr. Thomas O. Kleen

    Director, Business and Technology Development

    Cellular Technology Limited (CTL)

    Dr. Kleen is currently Director of Business and Technology Development at Cellular Technology Limited (CTL). Prior to this position, he was Director of Assay Development at CTL.
    His main expertise is in immunology, adjuvants and vaccine evaluation with a focus on high sensitivity T cell immune monitoring of novel vaccines and to detect adverse immune reactions to gene therapy and protein based drugs early. He spends significant time educating pharmaceutical entities and governmental agencies about validated, GLP compliant technologies, that are available today, for Immune Monitoring during pre-clinical and clinical trials.